aAll participants in the letermovir group received acyclovir for prophylaxis of herpes simplex and varicella-zoster virus.
bThe 95% CIs for the differences in proportions of participants were calculated using stratum-adjusted Mantel-Haenszel method with the difference weighted by the harmonic mean of sample size per group for each stratum (use/nonuse of lymphocyte-depleting induction immunosuppression). The upper bound of the 2-sided 95% CI for the primary outcome had to be no higher than 10% to conclude noninferiority. Participants who did not complete the study through week 52 or a had missing result for CMV DNAemia in the week-52 visit window were not considered failures (observed failure approach).
cCMV disease confirmed by the independent masked adjudication committee (CMV end-organ disease or CMV syndrome).
dPrespecified sensitivity analysis for investigator-reported CMV disease (included CMV syndrome and/or CMV end-organ disease).
eData were not available for 2 participants in the letermovir group and 1 participant in the valganciclovir group.